Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Trial StartCRB-701Positive

AI Analysis

Summary

Corbus Pharmaceuticals announced the first patient has been dosed in the TEMPO-1 registrational study of CRB-701 for patients with 2L+ oropharyngeal cancer. This marks the initiation of a pivotal trial for the investigational drug.

Clinical Trial Data

Phase

registrational

Outcome Details

First patient dosed in TEMPO-1 registrational study

Importance:5/10

Sentiment:

0.50

clinical trialoncologytrial enrollmentoropharyngeal cancer

Related Companies

$CRBP

Read the original article

Published by yahoo_finance on September 29, 2026 12:00 PM

Read Original